RXi, EyeGate Team Up

Xconomy Boston — 

RXi Pharmaceuticals (NASDAQ: RXII), a Worcester, MA-based developer of RNA interference treatments, said today it will collaborate with Waltham, MA-based EyeGate Pharma to deliver RNAi therapeutics to the eye for retinal disorders. Financial details weren’t given, but the partnership combines EyeGate’s expertise in delivering drugs into the eye non-invasively with RXi’s technology and resources in RNAi drugs and delivery methods. EyeGate raised a round of equity financing last December, while RXi appointed a new CEO, Noah Beerman, in November and raised $16.2 million in a stock sale in March 2010.